Stereotactic radiosurgery (SRS) and fractionated stereotactic body radiotherapy (SBRT) are effective
methods widely used in the treatment of brain, lung, liver, spine, and kidney tumors. The success of
these techniques requires high dosimetric and mechanical accuracy. CyberKnife, a robotic radiosurgery system developed at Stanford University, has been designed to meet these needs. CyberKnife works by
mounting a linear accelerator with 6 MV energy on an industrial robot arm. The device, which has a real-
time X-ray imaging system, tracks patient movements and directs radiation beams to the tumor with
high precision. This non-invasive method allows for high accuracy treatment of tumors without the need
for surgical intervention. This guide details the quality assurance (QA) procedures to ensure the safe and
effective use of CyberKnife. In line with the recommendations of the TG-135 task group of the American
Association of Physicists in Medicine and the manufacturer, QA tests classified as daily, monthly and
yearly should be applied regularly for CyberKnife systems. The addition of new technologies such as the
Iris? and InCise? collimators with the Xchange? collimator table has also necessitated additional quality
control procedures. CyberKnife represents a significant advance in cancer treatment. However, the effective
and safe operation of the system depends on QA procedures applied regularly in line with TG-135
recommendations. These tests aim to increase patient safety and maximize treatment effectiveness. This
guideline, based on the knowledge and experience of our experts working in different clinics in our country,
has been prepared in line with international guidelines with daily, monthly and annual QA tests of CyberKnife
determined in line with TG-135 recommendations and the manufacturer"s recommendations.
Keywords: Cyberknife; quality assurance; quality control
